TXG vs. BLI, BRKR, BIO, BIO.B, OLK, LAB, CTKB, QTRX, EYPT, and PACB
Should you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Berkeley Lights (BLI), Bruker (BRKR), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Olink Holding AB (publ) (OLK), Standard BioTools (LAB), Cytek Biosciences (CTKB), Quanterix (QTRX), EyePoint Pharmaceuticals (EYPT), and Pacific Biosciences of California (PACB). These companies are all part of the "analytical instruments" industry.
Berkeley Lights (NASDAQ:BLI) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
In the previous week, 10x Genomics had 10 more articles in the media than Berkeley Lights. MarketBeat recorded 10 mentions for 10x Genomics and 0 mentions for Berkeley Lights. Berkeley Lights' average media sentiment score of 0.80 beat 10x Genomics' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media.
10x Genomics received 33 more outperform votes than Berkeley Lights when rated by MarketBeat users. Likewise, 52.56% of users gave 10x Genomics an outperform vote while only 26.67% of users gave Berkeley Lights an outperform vote.
68.4% of Berkeley Lights shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 17.6% of Berkeley Lights shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Berkeley Lights has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Berkeley Lights, indicating that it is currently the more affordable of the two stocks.
Berkeley Lights has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
10x Genomics has a consensus price target of $48.50, indicating a potential upside of 116.32%.
10x Genomics has a net margin of -42.20% compared to 10x Genomics' net margin of -124.74%. Berkeley Lights' return on equity of -30.85% beat 10x Genomics' return on equity.
Summary
10x Genomics beats Berkeley Lights on 11 of the 15 factors compared between the two stocks.
Get 10x Genomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
10x Genomics Competitors List
Related Companies and Tools
